Over the last years, genome-wide association studies (GWAS) have significantly contributed to the characterization of the MS genetic component, with the identification of more than 200 genetic variants outside the major histocompatibility complex (MHC) that influence the risk of developing MS [2–5]. This evidence concerns the gene HLA-C and myeloid sarcoma.